REFERENCES
- Gilchrist V, McCord G, Schrop SL, Physician activities during time out of the examination room. Ann Fam Med. 2005;3:494–499.
- Tai-Seale M, McGuire TG, Zhang W. Time allocation in primary care office visits. Health Serv Res. 2007;42:1871–1894.
- Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004;112:65–75.
- Gourlay D, Heit H. Universal precautions: a matter of mutual trust and responsibility. Pain Med. 2006;7:210–211; author reply 212.
- Passik SD, Kirsh KL. The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp Clin Psychopharmacol. 2008;16:400–404.
- Passik SD, Kirsh KL. Managing pain in patients with aberrant drug-taking behaviors. J Support Oncol. 2005;3:83–86.
- Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract. 2008;4:4–25.
- Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6:432–442.
- Feldkamp CS. Immunochemical techniques. In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry: Theory, Analysis, Correlation. 5th ed. St. Louis, MO: Mosby; 2010:162–179.
- Garg U, Hammett-Stabler CA, eds. Clinical Applications of Mass Spectrometry: Methods and Protocols. Methods in Molecular Biology (Walker JM, ed.). 1st ed. Vol. 603. New York: Humana Press; 2010.
- Lehrer M. Chromatographic techniques. In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry: Theory, Analysis, Correlation. 5th ed. St. Louis, MO: Mosby; 2010:81–117.
- Thompson SG. Principles for competitive-binding assays. In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry: Theory, Analysis, Correlation. 5th ed. St. Louis, MO: Mosby; 2010:180–199.
- Wild D, ed. The Immunoassay Handbook: Theory and Applications of Ligand Binding, ELISA and Related Techniques. 4th ed. Oxford, UK: Elsevier; 2013.
- Substance Abuse and Mental Health Services Administration (SAMHSA). Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs. Rockville, MD: SAMHSA; Effective October 1, 2010.
- Laffer A, Murphy A, Winegarden W, An economic analysis of the costs and benefits associated with regular urine drug testing for chronic pain patients in the United States. Laffer Associates Executive Summary, xx, xx, 2011.
- McCarberg BH. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse. Postgrad Med. 2011;123:132–139.
- AIT Laboratories. Physician's Reference for Urine and Blood Drug Testing and Interpretation. xx, xx: AIT Laboratories; August 19, 2011. SMR086.
- Christo P, Manchikanti L, Ruan X, Urine drug testing in chronic pain: comprehensive review. Pain Physician. 2011;14:123–143.
- Global Analytics Development Proposed Test Menu.
- LabCorp. Drugs of abuse reference guide. Available at: https:// www.labcorp.com/wps/wcm/connect/24b476804b65af7fb49cb5 dc8b9b0898/L1123-0613-4.pdf?MOD=AJPERES&CACHEID =24b476804b65af7fb49cb5dc8b9b0898&CACHEID=457e14 004b2a17b4ba21bb1199be625c&CACHEID=457e14004b2a 17b4ba21bb1199be625c&CACHEID=457e14004b2a17b4ba 21bb1199be625c&. Accessed October 29, 2013.
- Marshfield Labs. Current cutoff levels for toxicology tests. Available at: https://www.marshfieldlabs.org/proxy/Current_Cutoff_ Levels_for_Toxicology_Tests.1.pdf. Accessed October 29, 2013.
- Quest Diagnostics. Drug Testing Solutions At-A-Glance. xx, xx: Quest Diagnostics; xxxx.
- Yang Z, Wang J, Ellis T. Interpretation of urine drug test for pain clinic: methodology and metabolism pathways of controlled substance. Am J Integr Med. 2012;2:21–35.